Anti-cancer therapies in high grade gliomas

Current Proteomics

Volumn 10, Issue 3, 2013, Pages 246-260

  Tanase, Cristiana Pistol ^a   Enciu, Ana Maria ^a,b   Mihai, Simona ^a   Neagu, Ana Iulia ^a,c   Calenic, Bogdan ^a,b   Cruceru, Maria Linda ^b  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

Author keywords

Antiangiogenic therapy; Cancer stem cells; Glioma; microRNA; Personalized medicine; PI 3K

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MICRORNA; MONOCLONAL ANTIBODY; NODAL SIGNALING PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TEMOZOLOMIDE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BRAIN RADIATION; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CANCER THERAPY; CELL DIFFERENTIATION; GLIOBLASTOMA; GLIOMA; HUMAN; LOCAL THERAPY; MOLECULAR THERAPY; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84892954243     PISSN: 15701646     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570164611310030007     Document Type: Review

References (165)

1. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W. and Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta. Neuropathol., 2007, 114(2), 97-109.
2. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E. and Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
3. Hide, T.; Takezaki, T.; Nakamura, H.; Kuratsu, J. and Kondo, T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol., 2008, 25(2), 67-72.
4. Roa, W.; Brasher, P. M.; Bauman, G.; Anthes, M.; Bruera, E.; Chan, A.; Fisher, B.; Fulton, D.; Gulavita, S.; Hao, C.; Husain, S.; Murtha, A.; Petruk, K.; Stewart, D.; Tai, P.; Urtasun, R.; Cairncross, J. G. and Forsyth, P. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol., 2004, 22(9), 1583-1588.
5. Tallet, A. V.; Azria, D.; Barlesi, F.; Spano, J. P.; Carpentier, A. F.; Goncalves, A. and Metellus, P. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat. Oncol., 2012, 7(77), 1-8.
6. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C. and Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352(10), 997-1003.
7. Wick, W.; Hartmann, C.; Engel, C.; Stoffels, M.; Felsberg, J.; Stockhammer, F.; Sabel, M. C.; Koeppen, S.; Ketter, R.; Meyermann, R.; Rapp, M.; Meisner, C.; Kortmann, R. D.; Pietsch, T.; Wiestler, O. D.; Ernemann, U.; Bamberg, M.; Reifenberger, G.; von Deimling, A. and Weller, M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol., 2009, 27(35), 5874-5880.
8. Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G. and Mirimanoff, R. O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10(5), 459-466.
9. Keime-Guibert, F.; Chinot, O.; Taillandier, L.; Cartalat-Carel, S.; Frenay, M.; Kantor, G.; Guillamo, J. S.; Jadaud, E.; Colin, P.; Bondiau, P. Y.; Menei, P.; Loiseau, H.; Bernier, V.; Honnorat, J.; Barrie, M.; Mokhtari, K.; Mazeron, J. J.; Bissery, A. and Delattre, J. Y. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med., 2007, 356(15), 1527-1535.
10. Shirai, K.; Siedow, M. R. and Chakravarti, A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J. Oncol., 2012, 2012(193436), 1-12.
11. Tuettenberg, J.; Friedel, C. and Vajkoczy, P. Angiogenesis in malignant glioma--a target for antitumor therapy? Crit. Rev. Oncol. Hematol., 2006, 59(3), 181-193.
12. Cea, V.; Sala, C. and Verpelli, C. Antiangiogenic therapy for glioma. J. Signal Transduct., 2012, 2012(483040), 1-15.
13. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A. B.; Shi, Q.; McLendon, R. E.; Bigner, D. D. and Rich, J. N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66(16), 7843-7848.
14. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y. and Jain, R. K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11(1), 83-95.
15. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E., 2nd; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D. D.; Friedman, A. H. and Friedman, H. S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res., 2007, 13(4), 1253-1259.
16. Jouanneau, E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery, 2008, 62(1), 31-52.
17. Lakka, S. S. and Rao, J. S. Antiangiogenic therapy in brain tumors. Expert Rev. Neurother., 2008, 8(10), 1457-1473.
18. de Groot, J. F. High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin. Cancer Res., 2011, 17(19), 6109-6111.
19. Chamberlain, M. C. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights Oncol., 2011, 5, 117-129.
20. Wen, P. Y. and Kesari, S. Malignant gliomas in adults. N. Engl. J. Med., 2008, 359(5), 492-507.
21. Saito, K.; Yoshida, K. and Toda, M. Brain Tumor Stem Cells and Anti-Angiogenic Therapy. In: Cancer Stem Cells-The Cutting Edge; Shostak PS, Ed.; InTech2011. p. 229-244.
22. Huang, T. T.; Sarkaria, S. M.; Cloughesy, T. F. and Mischel, P. S. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics, 2009, 6(3), 500-512.
23. MacDonald, T. J.; Aguilera, D. and Kramm, C. M. Treatment of high-grade glioma in children and adolescents. Neuro. Oncol., 2011, 13(10), 1049-1058.
24. Alentorn, A.; Marie, Y.; Carpentier, C.; Boisselier, B.; Giry, M.; Labussiere, M.; Mokhtari, K.; Hoang-Xuan, K.; Sanson, M.; Delattre, J. Y. and Idbaih, A. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro. Oncol., 2012, 14(11), 1393-1403.
25. Gschwind, A.; Fischer, O. M. and Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 361-370.
26. Lemmon, M. A. and Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141(7), 1117-1134.
27. Manning, B. D. and Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell, 2007, 129(7), 1261-1274.
28. Liu, P.; Cheng, H.; Roberts, T. M. and Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8(8), 627-644.
29. Cai, G.; Wong, R.; Chhieng, D.; Levy, G. H.; Gettinger, S. N.; Herbst, R. S.; Puchalski, J. T.; Homer, R. J. and Hui, P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol., 2013, 121(9), 500-507.
30. Jacobs, M. S.; Persons, D. L. and Fraga, G. R. EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study. J. Cutan. Pathol., 2013, 40(5), 447-454.
31. Gutierrez, C. and Schiff, R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med., 2011, 135(1), 55-62.
32. Yu, L.; Deng, L.; Li, J.; Zhang, Y. and Hu, L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol. Oncol., 2013, 128(2), 391-396.
33. Snuderl, M.; Fazlollahi, L.; Le, L. P.; Nitta, M.; Zhelyazkova, B. H.; Davidson, C. J.; Akhavanfard, S.; Cahill, D. P.; Aldape, K. D.; Betensky, R. A.; Louis, D. N. and Iafrate, A. J. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell, 2011, 20(6), 810-817.
34. Takeuchi, K. and Ito, F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull., 2011, 34(12), 1774-1780.
35. Toth, J.; Egervari, K.; Klekner, A.; Bognar, L.; Szanto, J.; Nemes, Z. and Szollosi, Z. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma. Pathol. Oncol. Res., 2009, 15(2), 225-229.
36. Verhaak, R. G.; Hoadley, K. A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M. D.; Miller, C. R.; Ding, L.; Golub, T.; Mesirov, J. P.; Alexe, G.; Lawrence, M.; O'Kelly, M.; Tamayo, P.; Weir, B. A.; Gabriel, S.; Winckler, W.; Gupta, S.; Jakkula, L.; Feiler, H. S.; Hodgson, J. G.; James, C. D.; Sarkaria, J. N.; Brennan, C.; Kahn, A.; Spellman, P. T.; Wilson, R. K.; Speed, T. P.; Gray, J. W.; Meyerson, M.; Getz, G.; Perou, C. M. and Hayes, D. N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17(1), 98-110.
37. Rao, S. K.; Edwards, J.; Joshi, A. D.; Siu, I. M. and Riggins, G. J. A survey of glioblastoma genomic amplifications and deletions. J. Neurooncol., 2010, 96(2), 169-179.
38. Rich, J. N.; Hans, C.; Jones, B.; Iversen, E. S.; McLendon, R. E.; Rasheed, B. K.; Dobra, A.; Dressman, H. K.; Bigner, D. D.; Nevins, J. R. and West, M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res., 2005, 65(10), 4051-4058.
39. Ekstrand, A. J.; Sugawa, N.; James, C. D. and Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc. Natl. Acad. Sci. U S A, 1992, 89(10), 4309-4313.
40. Frederick, L.; Wang, X. Y.; Eley, G. and James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res., 2000, 60(5), 1383-1387.
41. Cho, J.; Pastorino, S.; Zeng, Q.; Xu, X.; Johnson, W.; Vandenberg, S.; Verhaak, R.; Cherniack, A. D.; Watanabe, H.; Dutt, A.; Kwon, J.; Chao, Y. S.; Onofrio, R. C.; Chiang, D.; Yuza, Y.; Kesari, S. and Meyerson, M. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res., 2011, 71(24), 7587-7596.
42. Lee, J. C.; Vivanco, I.; Beroukhim, R.; Huang, J. H.; Feng, W. L.; DeBiasi, R. M.; Yoshimoto, K.; King, J. C.; Nghiemphu, P.; Yuza, Y.; Xu, Q.; Greulich, H.; Thomas, R. K.; Paez, J. G.; Peck, T. C.; Linhart, D. J.; Glatt, K. A.; Getz, G.; Onofrio, R.; Ziaugra, L.; Levine, R. L.; Gabriel, S.; Kawaguchi, T.; O'Neill, K.; Khan, H.; Liau, L. M.; Nelson, S. F.; Rao, P. N.; Mischel, P.; Pieper, R. O.; Cloughesy, T.; Leahy, D. J.; Sellers, W. R.; Sawyers, C. L.; Meyerson, M. and Mellinghoff, I. K. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med, 2006, 3(12), 2264-2273.
43. Taylor, T. E.; Furnari, F. B. and Cavenee, W. K. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr. Cancer Drug Targets, 2012, 12(3), 197-209.
44. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sorensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M. T. and Poulsen, H. S. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro. Oncol., 2010, 12(5), 508-516.
45. Lv, S.; Teugels, E.; Sadones, J.; De Brakeleer, S.; Duerinck, J.; Du Four, S.; Michotte, A.; De Greve, J. and Neyns, B. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int. J. Oncol., 2012, 41(3), 1029-1035.
46. Seshacharyulu, P.; Ponnusamy, M. P.; Haridas, D.; Jain, M.; Ganti, A. K. and Batra, S. K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16(1), 15-31.
47. Chakravarti, A.; Wang, M.; Robins, H. I.; Lautenschlaeger, T.; Curran, W. J.; Brachman, D. G.; Schultz, C. J.; Choucair, A.; Dolled-Filhart, M.; Christiansen, J.; Gustavson, M.; Molinaro, A.; Mischel, P.; Dicker, A. P.; Bredel, M. and Mehta, M. RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. Int. J. Radiat. Oncol. Biol. Phys., 2013, 85(5), 1206-1211.
48. Raizer, J. J.; Abrey, L. E.; Lassman, A. B.; Chang, S. M.; Lamborn, K. R.; Kuhn, J. G.; Yung, W. K.; Gilbert, M. R.; Aldape, K. A.; Wen, P. Y.; Fine, H. A.; Mehta, M.; Deangelis, L. M.; Lieberman, F.; Cloughesy, T. F.; Robins, H. I.; Dancey, J. and Prados, M. D. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro. Oncol., 2010, 12(1), 95-103.
49. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P. and Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6(4), 909-919.
50. Cleary, J. M. and Shapiro, G. I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr. Oncol. Rep., 2010, 12(2), 87-94.
51. Garlich, J. R.; De, P.; Dey, N.; Su, J. D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q. and Durden, D. L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68(1), 206-215.
52. Mahadevan, D.; Chiorean, E. G.; Harris, W. B.; Von Hoff, D. D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S. P.; Younger, A. E.; Rensvold, D. M.; Cordova, F.; Shelton, C. F.; Becker, M. D.; Garlich, J. R.; Durden, D. L. and Ramanathan, R. K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer, 2012, 48(18), 3319-3327.
53. De, P.; Dey, N.; Terakedis, B.; Bergsagel, P. L.; Li, Z. H.; Mahadevan, D.; Garlich, J. R.; Trudel, S.; Makale, M. T. and Durden, D. L. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother. Pharmacol., 2013, 71(4), 867-881.
54. McNamara, C. R. and Degterev, A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem, 2011, 3(5), 549-565.
55. McDowell, K. A.; Riggins, G. J. and Gallia, G. L. Targeting the AKT pathway in glioblastoma. Curr. Pharm. Des., 2011, 17(23), 2411-2420.
56. Koul, D.; Shen, R.; Bergh, S.; Sheng, X.; Shishodia, S.; Lafortune, T. A.; Lu, Y.; de Groot, J. F.; Mills, G. B. and Yung, W. K. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol. Cancer Ther., 2006, 5(3), 637-644.
57. Robinson, J. P.; Vanbrocklin, M. W.; McKinney, A. J.; Gach, H. M. and Holmen, S. L. Akt signaling is required for glioblastoma maintenance in vivo. Am. J. Cancer Res., 2011, 1(2), 155-167.
58. Yecies, J. L. and Manning, B. D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res., 2011, 71(8), 2815-2820.
59. Iwanami, A.; Gini, B.; Zanca, C.; Matsutani, T.; Assuncao, A.; Nael, A.; Dang, J.; Yang, H.; Zhu, S.; Kohyama, J.; Kitabayashi, I.; Cavenee, W. K.; Cloughesy, T. F.; Furnari, F. B.; Nakamura, M.; Toyama, Y.; Okano, H. and Mischel, P. S. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc. Natl. Acad. Sci. USA, 2013, 110(11), 4339-4344.
60. Fan, Q. W. and Weiss, W. A. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol. Biol., 2012, 821, 349-359.
61. Galan-Moya, E. M.; Le Guelte, A.; Lima Fernandes, E.; Thirant, C.; Dwyer, J.; Bidere, N.; Couraud, P. O.; Scott, M. G.; Junier, M. P.; Chneiweiss, H. and Gavard, J. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep., 2011, 12(5), 470-476.
62. Sunayama, J.; Sato, A.; Matsuda, K.; Tachibana, K.; Suzuki, K.; Narita, Y.; Shibui, S.; Sakurada, K.; Kayama, T.; Tomiyama, A. and Kitanaka, C. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro. Oncol., 2010, 12(12), 1205-1219.
63. Ellis, L. M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin. Oncol., 2006, 33(10), 1-7.
64. Hsu, J. Y. and Wakelee, H. A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs, 2009, 23(5), 289-304.
65. Schwartz, J. D.; Rowinsky, E. K.; Youssoufian, H.; Pytowski, B. and Wu, Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer, 2010, 116(4), 1027-1032.
66. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M. and Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther., 2008, 7(10), 3129-3140.
67. Pan, E.; Yu, D.; Yue, B.; Potthast, L.; Chowdhary, S.; Smith, P. and Chamberlain, M. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol., 2012, 110(1), 111-118.
68. Wick, W.; Weller, M.; Weiler, M.; Batchelor, T.; Yung, A. W. and Platten, M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro. Oncol., 2011, 13(6), 566-579.
69. Yang, X. D.; Jia, X. C.; Corvalan, J. R.; Wang, P. and Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol., 2001, 38(1), 17-23.
70. Thomas, S. M. and Grandis, J. R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev., 2004, 30(3), 255-268.
71. Ranson, M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer, 2004, 90(12), 2250-2255.
72. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J. and Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol. Cancer Ther., 2001, 1(2), 85-94.
73. Maira, S. M.; Stauffer, F.; Schnell, C. and Garcia-Echeverria, C. PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans., 2009, 37(Pt 1), 265-272.
74. Rhodes, N.; Heerding, D. A.; Duckett, D. R.; Eberwein, D. J.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Gilmer, T. M.; Zhang, S. Y.; Robell, K.; Kahana, J. A.; Geske, R. S.; Kleymenova, E. V.; Choudhry, A. E.; Lai, Z.; Leber, J. D.; Minthorn, E. A.; Strum, S. L.; Wood, E. R.; Huang, P. S.; Copeland, R. A. and Kumar, R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res., 2008, 68(7), 2366-2374.
75. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E. and Duggan, M. E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(3), 761-764.
76. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M. and Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67(12), 5840-5850.
77. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J. and Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51(18), 5522-5532.
78. Tolcher, A. W.; Messersmith, W. A.; Mikulski, S. M.; Papadopoulos, K. P.; Kwak, E. L.; Gibbon, D. G.; Patnaik, A.; Falchook, G. S.; Dasari, A.; Shapiro, G. I.; Boylan, J. F.; Xu, Z. X.; Wang, K.; Koehler, A.; Song, J.; Middleton, S. A.; Deutsch, J.; Demario, M.; Kurzrock, R. and Wheler, J. J. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol., 2012, 30(19), 2348-2353.
79. Hammond, S. M. RNAi, microRNAs, and human disease. Cancer Chemother. Pharmacol., 2006, 58(1), 63-68.
80. Deng, S.; Calin, G. A.; Croce, C. M.; Coukos, G. and Zhang, L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008, 7(17), 2643-2646.
81. Wang, Z.; Li, Y.; Kong, D.; Ahmad, A.; Banerjee, S. and Sarkar, F. H. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett, 2010, 292(2), 141-148.
82. Mizoguchi, M.; Guan, Y.; Yoshimoto, K.; Hata, N.; Amano, T.; Nakamizo, A. and Sasaki, T. Clinical implications of microRNAs in human glioblastoma. Front Oncol, 2013, 3(19), 1-6.
83. Hummel, R.; Maurer, J. and Haier, J. MicroRNAs in brain tumors: a new diagnostic and therapeutic perspective? Mol Neurobiol, 2011, 44(3), 223-34.
84. Papagiannakopoulos, T.; Friedmann-Morvinski, D.; Neveu, P.; Dugas, J. C.; Gill, R. M.; Huillard, E.; Liu, C.; Zong, H.; Rowitch, D. H.; Barres, B. A.; Verma, I. M. and Kosik, K. S. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene, 2012, 31(15), 1884-95.
85. Odjele, A.; Charest, D. and Morin, P., Jr. miRNAs as important drivers of glioblastomas: a no-brainer? Cancer Biomark, 2012, 11(6), 245-52.
86. Kim, T. M.; Huang, W.; Park, R.; Park, P. J. and Johnson, M. D. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res., 2011, 71(9), 3387-3399.
87. Wuchty, S.; Arjona, D.; Li, A.; Kotliarov, Y.; Walling, J.; Ahn, S.; Zhang, A.; Maric, D.; Anolik, R.; Zenklusen, J. C. and Fine, H. A. Prediction of Associations between microRNAs and Gene Expression in Glioma Biology. PLoS One, 2011, 6(2), 1-10.
88. Ma, X.; Yoshimoto, K.; Guan, Y.; Hata, N.; Mizoguchi, M.; Sagata, N.; Murata, H.; Kuga, D.; Amano, T.; Nakamizo, A. and Sasaki, T. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro. Oncol., 2012, 14(9), 1153-1162.
89. Krichevsky, A. M.; King, K. S.; Donahue, C. P.; Khrapko, K. and Kosik, K. S. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA, 2003, 9(10), 1274-1281.
90. Chan, J. A.; Krichevsky, A. M. and Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res., 2005, 65(14), 6029-6033.
91. Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A. K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; Cvijic, H.; Ullmann, A. K.; Stadler, P. F. and Horn, F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 2007, 110(4), 1330-1333.
92. Fujita, S.; Ito, T.; Mizutani, T.; Minoguchi, S.; Yamamichi, N.; Sakurai, K. and Iba, H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol., 2008, 378(3), 492-504.
93. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T. and Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133(2), 647-658.
94. Frankel, L. B.; Christoffersen, N. R.; Jacobsen, A.; Lindow, M.; Krogh, A. and Lund, A. H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem., 2008, 283(2), 1026-1033.
95. Gabriely, G.; Wurdinger, T.; Kesari, S.; Esau, C. C.; Burchard, J.; Linsley, P. S. and Krichevsky, A. M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol., 2008, 28(17), 5369-5380.
96. Zhu, S.; Wu, H.; Wu, F.; Nie, D.; Sheng, S. and Mo, Y. Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell. Res., 2008, 18(3), 350-359.
97. Medina, P. P. and Slack, F. J. microRNAs and cancer: an overview. Cell Cycle, 2008, 7(16), 2485-2492.
98. Papagiannakopoulos, T.; Shapiro, A. and Kosik, K. S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res., 2008, 68(19), 8164-8172.
99. Guan, Y.; Mizoguchi, M.; Yoshimoto, K.; Hata, N.; Shono, T.; Suzuki, S. O.; Araki, Y.; Kuga, D.; Nakamizo, A.; Amano, T.; Ma, X.; Hayashi, K. and Sasaki, T. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin. Cancer Res., 2010, 16(16), 4289-4297.
100. Godlewski, J.; Nowicki, M. O.; Bronisz, A.; Williams, S.; Otsuki, A.; Nuovo, G.; Raychaudhury, A.; Newton, H. B.; Chiocca, E. A. and Lawler, S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res., 2008, 68(22), 9125-9130.
101. Gabriely, G.; Yi, M.; Narayan, R. S.; Niers, J. M.; Wurdinger, T.; Imitola, J.; Ligon, K. L.; Kesari, S.; Esau, C.; Stephens, R. M.; Tannous, B. A. and Krichevsky, A. M. Human glioma growth is controlled by microRNA-10b. Cancer Res., 2011, 71(10), 3563-3572.
102. Guessous, F.; Alvarado-Velez, M.; Marcinkiewicz, L.; Zhang, Y.; Kim, J.; Heister, S.; Kefas, B.; Godlewski, J.; Schiff, D.; Purow, B. and Abounader, R. Oncogenic effects of miR-10b in glioblastoma stem cells. J. Neurooncol., 2013, 112(2), 153-163.
103. Sasayama, T.; Nishihara, M.; Kondoh, T.; Hosoda, K. and Kohmura, E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer, 2009, 125(6), 1407-1413.
104. Kosik, K. S. and Krichevsky, A. M. The Elegance of the MicroRNAs: A Neuronal Perspective. Neuron., 2005, 47(6), 779-782.
105. Mizoguchi, M.; Guan, Y.; Yoshimoto, K.; Hata, N.; Amano, T.; Nakamizo, A. and Sasaki, T. MicroRNAs in Human Malignant Gliomas. J. Oncol., 2012, 2012(732874), 1-7.
106. Wang, Q.; Li, P.; Li, A.; Jiang, W.; Wang, H.; Wang, J. and Xie, K. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J. Exp. Clin. Cancer Res., 2012, 31(97), 1-10.
107. Lu, J.; Getz, G.; Miska, E. A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B. L.; Mak, R. H.; Ferrando, A. A.; Downing, J. R.; Jacks, T.; Horvitz, H. R. and Golub, T. R. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043), 834-838.
108. Esquela-Kerscher, A. and Slack, F. J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 2006, 6(4), 259-269.
109. Calin, G. A. and Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 2006, 6(11), 857-866.
110. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A.; Lin, D. W.; Urban, N.; Drescher, C. W.; Knudsen, B. S.; Stirewalt, D. L.; Gentleman, R.; Vessella, R. L.; Nelson, P. S.; Martin, D. B. and Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U S A, 2008, 105(30), 10513-10518.
111. Purow, B. The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J. Neurooncol., 2011, 103(3), 429-436.
112. Bader, A. G.; Brown, D.; Stoudemire, J. and Lammers, P. Developing therapeutic microRNAs for cancer. Gene Ther., 2011, 18(12), 1121-1126.
113. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J. J. and Lotvall, J. O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 2007, 9(6), 654-659.
114. Kefas, B.; Godlewski, J.; Comeau, L.; Li, Y.; Abounader, R.; Hawkinson, M.; Lee, J.; Fine, H.; Chiocca, E. A.; Lawler, S. and Purow, B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res., 2008, 68(10), 3566-3572.
115. Bader, A. G. miR-34-a microRNA replacement therapy is headed to the clinic. Front. Genet., 2012, 3(120), 1-9.
116. Gaur, A. B.; Holbeck, S. L.; Colburn, N. H. and Israel, M. A. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro. Oncol., 2011, 13(6), 580-590.
117. Ren, Y.; Kang, C. S.; Yuan, X. B.; Zhou, X.; Xu, P.; Han, L.; Wang, G. X.; Jia, Z.; Zhong, Y.; Yu, S.; Sheng, J. and Pu, P. Y. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J. Biomater. Sci. Polym. Ed., 2010, 21(3), 303-314.
118. Ujifuku, K.; Mitsutake, N.; Takakura, S.; Matsuse, M.; Saenko, V.; Suzuki, K.; Hayashi, K.; Matsuo, T.; Kamada, K.; Nagata, I. and Yamashita, S. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett., 2010, 296(2), 241-248.
119. Binello, E. and Germano, I. M. Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci., 2011, 102(11), 1958-1966.
120. Salmaggi, A.; Boiardi, A.; Gelati, M.; Russo, A.; Calatozzolo, C.; Ciusani, E.; Sciacca, F. L.; Ottolina, A.; Parati, E. A.; La Porta, C.; Alessandri, G.; Marras, C.; Croci, D. and De Rossi, M. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 2006, 54(8), 850-860.
121. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis, S.; Fiocco, R.; Foroni, C.; Dimeco, F. and Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res., 2004, 64(19), 7011-7021.
122. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D. and Dirks, P. B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
123. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D. and Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
124. McCord, A. M.; Jamal, M.; Williams, E. S.; Camphausen, K. and Tofilon, P. J. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin. Cancer Res., 2009, 15(16), 5145-5153.
125. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T. L.; Fuller, C.; Hamner, B.; Oh, E. Y.; Gaber, M. W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I. T.; Zakharenko, S. S.; Gajjar, A.; Davidoff, A. and Gilbertson, R. J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.
126. Lee, J.; Son, M. J.; Woolard, K.; Donin, N. M.; Li, A.; Cheng, C. H.; Kotliarova, S.; Kotliarov, Y.; Walling, J.; Ahn, S.; Kim, M.; Totonchy, M.; Cusack, T.; Ene, C.; Ma, H.; Su, Q.; Zenklusen, J. C.; Zhang, W.; Maric, D. and Fine, H. A. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell, 2008, 13(1), 69-80.
127. Piccirillo, S. G.; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F. and Vescovi, A. L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature, 2006, 444(7120), 761-765.
128. Clark, P. A.; Treisman, D. M.; Ebben, J. and Kuo, J. S. Developmental signaling pathways in brain tumor-derived stemlike cells. Dev. Dyn., 2007, 236(12), 3297-3308.
129. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y. M. and Eberhart, C. G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 2006, 66(15), 7445-7452.
130. Shih, A. H. and Holland, E. C. Notch signaling enhances nestin expression in gliomas. Neoplasia, 2006, 8(12), 1072-1082.
131. Zhang, X. P.; Zheng, G.; Zou, L.; Liu, H. L.; Hou, L. H.; Zhou, P.; Yin, D. D.; Zheng, Q. J.; Liang, L.; Zhang, S. Z.; Feng, L.; Yao, L. B.; Yang, A. G.; Han, H. and Chen, J. Y. Notch activation promotes cell proliferation and the formation of neural stem celllike colonies in human glioma cells. Mol. Cell. Biochem., 2008, 307(1-2), 101-108.
132. Bar, E. E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A. L.; DiMeco, F.; Olivi, A. and Eberhart, C. G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 2007, 25(10), 2524-2533.
133. Clement, V.; Sanchez, P.; de Tribolet, N.; Radovanovic, I. and Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 2007, 17(2), 165-172.
134. Eyler, C. E.; Foo, W. C.; LaFiura, K. M.; McLendon, R. E.; Hjelmeland, A. B. and Rich, J. N. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells, 2008, 26(12), 3027-3036.
135. Hambardzumyan, D.; Squatrito, M.; Carbajal, E. and Holland, E. C. Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev., 2008, 4(3), 203-210.
136. Folkins, C.; Man, S.; Xu, P.; Shaked, Y.; Hicklin, D. J. and Kerbel, R. S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res., 2007, 67(8), 3560-3564.
137. Liu, Y.; Wu, C.; Lyu, Q.; Yang, D.; Albertini, D. F.; Keefe, D. L. and Liu, L. Germline stem cells and neo-oogenesis in the adult human ovary. Dev. Biol., 2007, 306(1), 112-120.
138. Rahman, M.; Hoh, B.; Kohler, N.; Dunbar, E. M. and Murad, G. J. The future of glioma treatment: stem cells, nanotechnology and personalized medicine. Future Oncol., 2012, 8(9), 1149-1156.
139. Fan, X.; Khaki, L.; Zhu, T. S.; Soules, M. E.; Talsma, C. E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y. M.; Maciaczyk, J.; Nikkhah, G.; Dimeco, F.; Piccirillo, S.; Vescovi, A. L. and Eberhart, C. G. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 2010, 28(1), 5-16.
140. Bengzon, J.; Englund, E.; Salford, L. and Xialong, F. In: Glioma Stem Cells in the Context of Oncogenesis.
141. Bagley R, Teicher B, editors. Stem Cells and Cancer; Humana Press: Framingham, MA, 2009; Vol. pp. 115-1126.
142. Sell, S. Cancer stem cells and differentiation therapy. Tumour Biol., 2006, 27(2), 59-70.
143. Zhong, S.; Salomoni, P. and Pandolfi, P. P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol., 2000, 2(5), E85-90.
144. Bianchi, M. G.; Gazzola, G. C.; Tognazzi, L. and Bussolati, O. C6 glioma cells differentiated by retinoic acid overexpress the glutamate transporter excitatory amino acid carrier 1 (EAAC1). Neuroscience, 2008, 151(4), 1042-1052.
145. Deng, H.; Zou, F. and Luo, H. J. Differentiation of neonatal rat striatal neural stem cells induced by all-trans retinoic acid. Di Yi Jun Yi Da Xue Xue Bao, 2005, 25(11), 1357-1360.
146. Wang, F.; Li, S. T.; Huang, Q. and Lan, Q. Expression of Notch1 gene in the differentiation of the human embryonic neural stem cells to neurons. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2004, 20(6), 769-772.
147. Shen, Q.; Goderie, S. K.; Jin, L.; Karanth, N.; Sun, Y.; Abramova, N.; Vincent, P.; Pumiglia, K. and Temple, S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science, 2004, 304(5675), 1338-1340.
148. Okada, H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann. N. Y. Acad. Sci., 2009, 1174, 18-23.
149. Yang, I.; Han, S. and Parsa, A. T. Heat-shock protein vaccines as active immunotherapy against human gliomas. Expert Rev. Anticancer Ther., 2009, 9(11), 1577-1582.
150. Soling, A. and Rainov, N. G. Dendritic cell therapy of primary brain tumors. Mol. Med., 2001, 7(10), 659-667.
151. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I. R.; Lu, L.; Irvin, D.; Black, K. L. and Yu, J. S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5(67), 1-12.
152. Yu, J. S.; Liu, G.; Ying, H.; Yong, W. H.; Black, K. L. and Wheeler, C. J. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res., 2004, 64(14), 4973-4979.
153. Liau, L. M.; Prins, R. M.; Kiertscher, S. M.; Odesa, S. K.; Kremen, T. J.; Giovannone, A. J.; Lin, J. W.; Chute, D. J.; Mischel, P. S.; Cloughesy, T. F. and Roth, M. D. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res., 2005, 11(15), 5515-5525.
154. Pellegatta, S.; Poliani, P. L.; Corno, D.; Menghi, F.; Ghielmetti, F.; Suarez-Merino, B.; Caldera, V.; Nava, S.; Ravanini, M.; Facchetti, F.; Bruzzone, M. G. and Finocchiaro, G. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res., 2006, 66(21), 10247-10252.
155. Schmitz, M.; Temme, A.; Senner, V.; Ebner, R.; Schwind, S.; Stevanovic, S.; Wehner, R.; Schackert, G.; Schackert, H. K.; Fussel, M.; Bachmann, M.; Rieber, E. P. and Weigle, B. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br. J. Cancer, 2007, 96(8), 1293-1301.
156. Neagu, M.; Constantin, C. and Tanase, C. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev. Mol. Diagn., 2010, 10(7), 897-919.
157. Masui, K.; Cloughesy, T. F. and Mischel, P. S. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol., 2012, 38(3), 271-291.
158. Haas-Kogan, D. A.; Prados, M. D.; Tihan, T.; Eberhard, D. A.; Jelluma, N.; Arvold, N. D.; Baumber, R.; Lamborn, K. R.; Kapadia, A.; Malec, M.; Berger, M. S. and Stokoe, D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst., 2005, 97(12), 880-887.
159. Fan, Q. W.; Cheng, C.; Knight, Z. A.; Haas-Kogan, D.; Stokoe, D.; James, C. D.; McCormick, F.; Shokat, K. M. and Weiss, W. A. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal., 2009, 2(55), 1-19.
160. Wang, M. Y.; Lu, K. V.; Zhu, S.; Dia, E. Q.; Vivanco, I.; Shackleford, G. M.; Cavenee, W. K.; Mellinghoff, I. K.; Cloughesy, T. F.; Sawyers, C. L. and Mischel, P. S. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTENintact glioblastoma cells. Cancer Res., 2006, 66(16), 7864-7869.
161. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L. and DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318(5848), 287-290.
162. Chandarlapaty, S.; Sawai, A.; Scaltriti, M.; Rodrik-Outmezguine, V.; Grbovic-Huezo, O.; Serra, V.; Majumder, P. K.; Baselga, J. and Rosen, N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell, 2011, 19(1), 58-71.
163. Perri, F.; Cotugno, R.; Piepoli, A.; Merla, A.; Quitadamo, M.; Gentile, A.; Pilotto, A.; Annese, V. and Andriulli, A. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am. J. Gastroenterol., 2007, 102(7), 1361-1371.
164. Jin, L.; Hope, K. J.; Zhai, Q.; Smadja-Joffe, F. and Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med., 2006, 12(10), 1167-1174.
165. Gal, H.; Pandi, G.; Kanner, A. A.; Ram, Z.; Lithwick-Yanai, G.; Amariglio, N.; Rechavi, G. and Givol, D. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun., 2008, 376(1), 86-90.